A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- Registration Number
- NCT04242498
- Lead Sponsor
- UCB Biopharma SRL
- Brief Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 509
-
Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative
-
Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit
-
Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits
-
Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits
-
Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history
-
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of investigational medicinal product (IMP)
- Draining tunnel count of >20 at the Baseline Visit
- Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
- Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
- Primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
- Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- Active infection or history of certain infection(s)
- Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
- Concurrent malignancy. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
- History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
- Known hypersensitivity to any components of bimekizumab or comparative drugs as stated in this protocol this protocol
- Concomitant and prior medication restrictions
- Myocardial infarction or stroke within the 6 months prior to the Screening Visit
- Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
- Presence of moderately severe major depression or severe major depression
- Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Group Placebo Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period. Bimekizumab dosing regimen 1 Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period. Bimekizumab dosing regimen 2 Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period. Placebo Group Bimekizumab Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period. Bimekizumab dosing regimen 3 Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 Week 16 HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 Week 16 HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
Percentage of Participants With Flare by Week 16 From Baseline to Week 16 Flare was defined as a greater than or equal to (\>=) 25% increase in AN count with an absolute increase in AN count of \>= 2 relative to Baseline. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event prior to experiencing a flare were treated as having experienced a flare at all flare assessments on and after the intercurrent event date. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 Baseline, Week 16 The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.
Absolute Change From Baseline in Worst Skin Pain Score at Week 16 Baseline, Week 16 Absolute change from Baseline in worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.
Percentage of Participants Achieving Skin Pain Response at Week 16 Week 16 Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentages of participants shown do not account for model effects using logistic regression model.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study From Baseline (Day 1) until Safety Follow-Up (up to Week 71) An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study From Baseline (Day 1) until Safety Follow-Up (up to Week 71) A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study From Baseline (Day 1) until Safety Follow-Up (up to Week 71) An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.
Trial Locations
- Locations (91)
Hs0004 50184
🇺🇸Pembroke Pines, Florida, United States
Hs0004 50223
🇺🇸Savannah, Georgia, United States
Hs0004 50199
🇺🇸Miami, Florida, United States
Hs0004 40245
🇫🇷Antony, France
Hs0004 40254
🇭🇺Debrecen, Hungary
Hs0004 40250
🇩🇪Lübeck, Germany
Hs0004 40321
🇫🇷Auxerre, France
Hs0004 50202
🇺🇸Fairborn, Ohio, United States
Hs0004 50197
🇺🇸Henderson, Nevada, United States
Hs0004 50200
🇺🇸Verona, New Jersey, United States
Hs0004 50236
🇺🇸Greenville, South Carolina, United States
Hs0004 50084
🇺🇸Johns Island, South Carolina, United States
Hs0004 20144
🇯🇵Fukuoka, Japan
Hs0004 20154
🇯🇵Sapporo, Japan
Hs0004 40335
🇵🇱Warszawa, Poland
Hs0004 40095
🇵🇱Wroclaw, Poland
Hs0004 20196
🇯🇵Bunkyo-ku, Japan
Hs0004 40353
🇧🇬Stara Zagora, Bulgaria
Hs0004 50159
🇺🇸Portsmouth, New Hampshire, United States
Hs0004 20090
🇮🇱Afula, Israel
Hs0004 40314
🇧🇬Sofia, Bulgaria
Hs0004 40313
🇧🇬Pleven, Bulgaria
Hs0004 40284
🇧🇬Sofia, Bulgaria
Hs0004 40311
🇧🇬Sofia, Bulgaria
Hs0004 40315
🇧🇬Sofia, Bulgaria
Hs0004 20033
🇯🇵Nagoya, Japan
Hs0004 20153
🇯🇵Obihiro, Japan
Hs0004 20171
🇯🇵Sendai, Japan
Hs0004 40333
🇵🇱Wroclaw, Poland
Hs0004 40334
🇵🇱Wroclaw, Poland
Hs0004 20043
🇯🇵Itabashi-ku, Japan
Hs0004 20195
🇯🇵Kagoshima, Japan
Hs0004 20170
🇯🇵Kurume, Japan
Hs0004 20152
🇯🇵Nakagami-gun, Japan
Hs0004 20190
🇯🇵Kyoto, Japan
Hs0004 20037
🇯🇵Osaka, Japan
Hs0004 40347
🇵🇱Lodz, Poland
Hs0004 40293
🇵🇱Rzeszow, Poland
Hs0004 40320
🇫🇷La Rochelle, France
Hs0004 40344
🇮🇪Dublin, Ireland
Hs0004 40297
🇪🇸Manises, Spain
Hs0004 50196
🇺🇸Thousand Oaks, California, United States
Hs0004 50162
🇺🇸Fountain Valley, California, United States
Hs0004 50152
🇺🇸Orange Park, Florida, United States
Hs0004 50193
🇺🇸Sandy Springs, Georgia, United States
Hs0004 50144
🇺🇸Orlando, Florida, United States
Hs0004 50164
🇺🇸Skokie, Illinois, United States
Hs0004 50234
🇺🇸Plainfield, Indiana, United States
Hs0004 50178
🇺🇸Clarkston, Michigan, United States
Hs0004 50105
🇺🇸Saint Louis, Missouri, United States
Hs0004 50211
🇺🇸Durham, North Carolina, United States
Hs0004 50237
🇺🇸Albuquerque, New Mexico, United States
Hs0004 50145
🇺🇸Columbus, Ohio, United States
Hs0004 50150
🇺🇸Philadelphia, Pennsylvania, United States
Hs0004 50179
🇺🇸Winston-Salem, North Carolina, United States
Hs0004 50148
🇺🇸Pflugerville, Texas, United States
Hs0004 30014
🇦🇺St Leonards, Australia
Hs0004 30018
🇦🇺Parkville, Australia
Hs0004 30009
🇦🇺Westmead, Australia
Hs0004 40063
🇨🇿Praha 5, Czechia
Hs0004 50172
🇨🇦Cobourg, Canada
Hs0004 40194
🇨🇿Praha 10, Czechia
Hs0004 50134
🇨🇦Waterloo, Canada
Hs0004 50189
🇨🇦St. John's, Canada
Hs0004 50135
🇨🇦Edmonton, Canada
Hs0004 50174
🇨🇦London, Canada
Hs0004 50136
🇨🇦Winnipeg, Canada
Hs0004 40129
🇫🇷Bordeaux Cedex, France
Hs0004 40247
🇫🇷Lyon, France
Hs0004 40403
🇫🇷Saint-etienne, France
Hs0004 40130
🇫🇷Marseille, France
Hs0004 40404
🇫🇷Reims, France
Hs0004 40289
🇩🇪Berlin, Germany
Hs0004 40326
🇩🇪Berlin, Germany
Hs0004 40286
🇫🇷Toulouse, France
Hs0004 40322
🇩🇪Dessau, Germany
Hs0004 40356
🇩🇪Dresden, Germany
Hs0004 40287
🇩🇪Frankfurt/main, Germany
Hs0004 40142
🇩🇪Hamburg, Germany
Hs0004 40328
🇩🇪Hannover, Germany
Hs0004 20178
🇯🇵Nishinomiya, Japan
Hs0004 40267
🇪🇸Barcelona, Spain
Hs0004 40268
🇪🇸Madrid, Spain
Hs0004 40159
🇪🇸Barcelona, Spain
Hs0004 40298
🇪🇸Granada, Spain
Hs0004 40101
🇪🇸Sabadell, Spain
Hs0004 40300
🇬🇧Cardiff, United Kingdom
Hs0004 40113
🇬🇧London, United Kingdom
Hs0004 40339
🇬🇧Leeds, United Kingdom
Hs0004 40240
🇬🇧Newcastle Upon Tyne, United Kingdom
Hs0004 40338
🇬🇧Northampton, United Kingdom